Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats

Bushra Wali, Tauheed Ishrat, Fahim Atif, Fang Hua, Donald G. Stein, Iqbal Sayeed

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Studies from a single laboratory have shown that in rodent models of permanent stroke, administration of the sulfonylurea glibenclamide (Glib) is highly effective in reducing edema, mortality, and lesion volume. The Stroke Therapy Academic Industry Roundtable (STAIR) recommends that new acute treatments for ischemic stroke to be replicated across different laboratories. Accordingly, we examined the effect of low-dose Glib in a permanent suture occlusion model of stroke. Male Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO) followed by an initial intraperitoneal injection of Glib (10 μg/kg) and the start of a constant infusion (200 ng/h) via miniosmotic pump at the onset of ischemia. Functional deficits were assessed by Neurological Severity Score (NSS) and grip-strength meter at 24 and 48 h after pMCAO. Glib-treated rats showed a significant reduction in infarct volume, lower NSS, and less hemispheric swelling compared to vehicle. Grip strength was decreased significantly in pMCAO rats compared to shams and significantly improved by treatment with Glib. Taken together, these data indicate that Glib has strong neuroprotective effects following ischemic stroke and may warrant further testing in future clinical trials for human stroke.

Original languageEnglish (US)
Article number460909
JournalStroke Research and Treatment
DOIs
StatePublished - Oct 17 2012
Externally publishedYes

Fingerprint

Glyburide
Brain Ischemia
Stroke
Middle Cerebral Artery Infarction
Hand Strength
Neuroprotective Agents
Intraperitoneal Injections
Sutures
Sprague Dawley Rats
Rodentia
Edema
Industry
Therapeutics
Ischemia
Clinical Trials
Mortality

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. / Wali, Bushra; Ishrat, Tauheed; Atif, Fahim; Hua, Fang; Stein, Donald G.; Sayeed, Iqbal.

In: Stroke Research and Treatment, 17.10.2012.

Research output: Contribution to journalArticle

@article{233e3d8025c34e44b1977d103a1b93bb,
title = "Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats",
abstract = "Studies from a single laboratory have shown that in rodent models of permanent stroke, administration of the sulfonylurea glibenclamide (Glib) is highly effective in reducing edema, mortality, and lesion volume. The Stroke Therapy Academic Industry Roundtable (STAIR) recommends that new acute treatments for ischemic stroke to be replicated across different laboratories. Accordingly, we examined the effect of low-dose Glib in a permanent suture occlusion model of stroke. Male Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO) followed by an initial intraperitoneal injection of Glib (10 μg/kg) and the start of a constant infusion (200 ng/h) via miniosmotic pump at the onset of ischemia. Functional deficits were assessed by Neurological Severity Score (NSS) and grip-strength meter at 24 and 48 h after pMCAO. Glib-treated rats showed a significant reduction in infarct volume, lower NSS, and less hemispheric swelling compared to vehicle. Grip strength was decreased significantly in pMCAO rats compared to shams and significantly improved by treatment with Glib. Taken together, these data indicate that Glib has strong neuroprotective effects following ischemic stroke and may warrant further testing in future clinical trials for human stroke.",
author = "Bushra Wali and Tauheed Ishrat and Fahim Atif and Fang Hua and Stein, {Donald G.} and Iqbal Sayeed",
year = "2012",
month = "10",
day = "17",
doi = "10.1155/2012/460909",
language = "English (US)",
journal = "Stroke Research and Treatment",
issn = "2090-8105",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats

AU - Wali, Bushra

AU - Ishrat, Tauheed

AU - Atif, Fahim

AU - Hua, Fang

AU - Stein, Donald G.

AU - Sayeed, Iqbal

PY - 2012/10/17

Y1 - 2012/10/17

N2 - Studies from a single laboratory have shown that in rodent models of permanent stroke, administration of the sulfonylurea glibenclamide (Glib) is highly effective in reducing edema, mortality, and lesion volume. The Stroke Therapy Academic Industry Roundtable (STAIR) recommends that new acute treatments for ischemic stroke to be replicated across different laboratories. Accordingly, we examined the effect of low-dose Glib in a permanent suture occlusion model of stroke. Male Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO) followed by an initial intraperitoneal injection of Glib (10 μg/kg) and the start of a constant infusion (200 ng/h) via miniosmotic pump at the onset of ischemia. Functional deficits were assessed by Neurological Severity Score (NSS) and grip-strength meter at 24 and 48 h after pMCAO. Glib-treated rats showed a significant reduction in infarct volume, lower NSS, and less hemispheric swelling compared to vehicle. Grip strength was decreased significantly in pMCAO rats compared to shams and significantly improved by treatment with Glib. Taken together, these data indicate that Glib has strong neuroprotective effects following ischemic stroke and may warrant further testing in future clinical trials for human stroke.

AB - Studies from a single laboratory have shown that in rodent models of permanent stroke, administration of the sulfonylurea glibenclamide (Glib) is highly effective in reducing edema, mortality, and lesion volume. The Stroke Therapy Academic Industry Roundtable (STAIR) recommends that new acute treatments for ischemic stroke to be replicated across different laboratories. Accordingly, we examined the effect of low-dose Glib in a permanent suture occlusion model of stroke. Male Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO) followed by an initial intraperitoneal injection of Glib (10 μg/kg) and the start of a constant infusion (200 ng/h) via miniosmotic pump at the onset of ischemia. Functional deficits were assessed by Neurological Severity Score (NSS) and grip-strength meter at 24 and 48 h after pMCAO. Glib-treated rats showed a significant reduction in infarct volume, lower NSS, and less hemispheric swelling compared to vehicle. Grip strength was decreased significantly in pMCAO rats compared to shams and significantly improved by treatment with Glib. Taken together, these data indicate that Glib has strong neuroprotective effects following ischemic stroke and may warrant further testing in future clinical trials for human stroke.

UR - http://www.scopus.com/inward/record.url?scp=84867386028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867386028&partnerID=8YFLogxK

U2 - 10.1155/2012/460909

DO - 10.1155/2012/460909

M3 - Article

JO - Stroke Research and Treatment

JF - Stroke Research and Treatment

SN - 2090-8105

M1 - 460909

ER -